1-20 of 54
Jeffrey A. Engelman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Jennifer L. Cotton, Javier Estrada Diez, Vivek Sagar, Julie Chen, Michelle Piquet, John Alford, Youngchul Song, Xiaoyan Li, Markus Riester, Matthew T. DiMare, Katja Schumacher, Gaylor Boulay, Kathleen Sprouffske, Lin Fan, Tyler Burks, Leandra Mansur, Joel Wagner, Hyo-eun C. Bhang, Oleg Iartchouk, John Reece-Hoyes, Erick J. Morris, Peter S. Hammerman, David A. Ruddy, Joshua M. Korn, Jeffrey A. Engelman, Matthew J. Niederst
Journal: Cancer Research
Cancer Res (2023) 83 (21): 3611–3623.
https://doi.org/10.1158/0008-5472.CAN-23-0144
Published: 01 November 2023
View article titled, Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
Open the PDF for Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance in another window
Includes: Supplementary data
Journal Articles

Abstract PO-100: Expressed molecular barcoding coupled with single cell RNAseq enables a high resolution investigation into the evolution of drug tolerance

Jennifer L. Cotton, Viveksagar Krisnamurthy Radhakrishna, Javier Estrada Diez, David A. Ruddy, Kathleen Sprouffske, Gaylor Boulay, Michelle Piquet, Joel Wagner, Youngchul Song, Xiaoyan Li, Katja Schumacher, Joshua Korn, Erick J. Morris, Peter S. Hammerman, Jeffrey A. Engelman, Matthew J. Niederst
Journal: Cancer Research
Cancer Res (2020) 80 (21_Supplement): PO-100.
https://doi.org/10.1158/1538-7445.TUMHET2020-PO-100
Published: 03 November 2020
View article titled, Abstract PO-100: Expressed molecular barcoding coupled with single cell RNAseq enables a high resolution investigation into the evolution of drug tolerance
Journal Articles

A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts

Adam C. Palmer, Deborah Plana, Hui Gao, Joshua M. Korn, Guizhi Yang, John Green, Xiamei Zhang, Roberto Velazquez, Margaret E. McLaughlin, David A. Ruddy, Colleen Kowal, Julie Muszynski, Caroline Bullock, Stacy Rivera, Daniel P. Rakiec, GiNell Elliott, Paul Fordjour, Ronald Meyer, Alice Loo, Esther Kurth, Jeffrey A. Engelman, Hans Bitter, William R. Sellers, Juliet A. Williams, Peter K. Sorger
Journal: Cancer Research
Cancer Res (2020) 80 (19): 4278–4287.
https://doi.org/10.1158/0008-5472.CAN-19-3850
Published: 02 October 2020
View article titled, A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
Open the PDF for A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer

Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino-Kenudson, James Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1903.
https://doi.org/10.1158/1538-7445.AM2020-1903
Published: 15 August 2020
View article titled, Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer
Journal Articles

Abstract 394: In vivo shRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies for BRAF-mutant colorectal cancer

Hyo-eun C. Bhang, Matthew T. DiMare, David P. Kodack, Lujian Tan, Grainne Kerr, Viveksagar Krishnamurthy Radhakrishna, Javad Golji, David A. Ruddy, Tina Yuan, Matthew J. Niederst, Joshua M. Korn, Diana Graus Porta, Peter S. Hammerman, Jeffrey A. Engelman, Tinya Abrams, Juliet Williams
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 394.
https://doi.org/10.1158/1538-7445.AM2019-394
Published: 01 July 2019
View article titled, Abstract 394: <em>In vivo</em> shRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies for <em>BRAF</em>-mutant colorectal cancer
Journal Articles

Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors

Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas M. Dunkl, Malika Kazic-Legueux, Anne Haberkorn, Eric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huaixiang Hao
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 954.
https://doi.org/10.1158/1538-7445.AM2019-954
Published: 01 July 2019
View article titled, Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors
Journal Articles

Abstract LB-259: FGFR- and EGFR-driven SHP2 activation displays differential sensitivity to allosteric SHP2 inhibition

Huaixiang Hao, Hengyu Lu, Chen Liu, Matthew LaMarche, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-259.
https://doi.org/10.1158/1538-7445.AM2019-LB-259
Published: 01 July 2019
View article titled, Abstract LB-259: FGFR- and EGFR-driven SHP2 activation displays differential sensitivity to allosteric SHP2 inhibition
Journal Articles

Abstract 101: Adaptive feedback reactivates MAPK signaling in KRAS-mutant cancers with inhibition of MEK, but not ERK

Leanne G. Ahronian, Sandra Misale, Jason T. Godfrey, Koki Nishimura, Lifeng Chen, Jeffrey A. Engelman, Ryan B. Corcoran
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 101.
https://doi.org/10.1158/1538-7445.AM2017-101
Published: 01 July 2017
View article titled, Abstract 101: Adaptive feedback reactivates MAPK signaling in KRAS-mutant cancers with inhibition of MEK, but not ERK
Journal Articles

Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)

Leila Dardaei, Hui Qin Wang, Paul Fordjour, Manrose Singh, Grainne Kerr, Satoshi Yoda, Jinsheng Liang, Yichen Cao, Yan Chen, Justin F. Gainor, Luc Friboulet, Ibiayi Dagogo-Jack, David T. Myers, Emma Labrot, David Ruddy, Melissa Parks, Dana Lee, Richard H. DiCecca, Susan Moody, Huaixiang Hao, Morvarid Mohseni, Matthew LaMarche, Juliet Williams, Keith Hoffmaster, Giordano Caponigro, Cyril H. Benes, Alice T. Shaw, Aaron N. Hata, Fang Li, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1007.
https://doi.org/10.1158/1538-7445.AM2017-1007
Published: 01 July 2017
View article titled, Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)
Journal Articles

Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors

Andreas Weiss, Diana Graus Porta, Flavia Reimann, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Jacqueline Kinyamu-Akunda, Dario Sterker, Masato Murakami, Markus Wartmann, Youzhen Wang, Jeffrey A. Engelman, Francesco Hofmann, Wiliam R. Sellers
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2103.
https://doi.org/10.1158/1538-7445.AM2017-2103
Published: 01 July 2017
View article titled, Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors
Journal Articles

Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib

Satoshi Yoda, Leila Dardaei, Manrose Singh, Jeffrey A. Engelman, Alice T. Shaw, Aaron N. Hata
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3144.
https://doi.org/10.1158/1538-7445.AM2017-3144
Published: 01 July 2017
View article titled, Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib
Journal Articles

Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

Gino B. Ferraro, David P. Kodack, Vasileios Askoxylakis, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Alexander Z. Cao, Rakesh R. Ramjiawan, Divya Bezwada, Bhushankumar Patel, Youngchul Song, Carlotta Costa, Kamila Naxerova, Christina Wong, Jonas Kloepper, Rita Das, Angela Tam, Jantima Tanboon, Dan G. Duda, Ryan C. Miller, Marni B. Siegel, Carey K. Anders, Melinda Sanders, Valeria M. Estrada, Robert Schlegel, Carlos L. Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5008.
https://doi.org/10.1158/1538-7445.AM2017-5008
Published: 01 July 2017
View article titled, Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
Journal Articles

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Daniele Oddo, Erin M. Sennott, Ludovic Barault, Emanuele Valtorta, Sabrina Arena, Andrea Cassingena, Genny Filiciotto, Giulia Marzolla, Elena Elez, Robin M.J.M. van Geel, Alice Bartolini, Giovanni Crisafulli, Valentina Boscaro, Jason T. Godfrey, Michela Buscarino, Carlotta Cancelliere, Michael Linnebacher, Giorgio Corti, Mauro Truini, Giulia Siravegna, Julieta Grasselli, Margherita Gallicchio, René Bernards, Jan H.M. Schellens, Josep Tabernero, Jeffrey A. Engelman, Andrea Sartore-Bianchi, Alberto Bardelli, Salvatore Siena, Ryan B. Corcoran, Federica Di Nicolantonio
Journal: Cancer Research
Cancer Res (2016) 76 (15): 4504–4515.
https://doi.org/10.1158/0008-5472.CAN-16-0396
Published: 31 July 2016
View article titled, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <em>BRAF</em>-Mutant Colorectal Cancer
Open the PDF for Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <em>BRAF</em>-Mutant Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 7: LKB1 deficiency is associated with a unique metabolic signature in Kras mutant non-small cell lung cancer (NSCLC)

Tingyu Liu, Erin Sennott, Zhengjie Zhong, Mya Steadman, Kelly Marsh, Jonathan Hurov, Cyril Benes, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 7.
https://doi.org/10.1158/1538-7445.AM2016-7
Published: 15 July 2016
View article titled, Abstract 7: LKB1 deficiency is associated with a unique metabolic signature in Kras mutant non-small cell lung cancer (NSCLC)
Journal Articles

Abstract 4184: Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition

Jiehui Deng, Shuai Li, Grit Herter-Sprie, Paul D. Smith, Gordon J. Freeman, Jeffrey A. Engelman, Peter Hammerman, Kwok-Kin Wong
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4184.
https://doi.org/10.1158/1538-7445.AM2016-4184
Published: 15 July 2016
View article titled, Abstract 4184: Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition
Journal Articles

Abstract 291: Single cell analyses reveal resistance heterogeneity in EGFR mutant NSCLC

Matt J. Niederst, Huidan Zhang, Haichuan Hu, Naiwen Cui, Yamei Cai, Hillary Mulvey, Zofia Piotrowska, Lecia Sequist, David A. Weitz, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 291.
https://doi.org/10.1158/1538-7445.AM2016-291
Published: 15 July 2016
View article titled, Abstract 291: Single cell analyses reveal resistance heterogeneity in EGFR mutant NSCLC
Journal Articles

Abstract A48: Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice

Gino B. Ferraro, Vasileios Askoxylakis, David P. Kodack, Mark Badeaux, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2016) 76 (7_Supplement): A48.
https://doi.org/10.1158/1538-7445.TUMMET15-A48
Published: 26 May 2016
View article titled, Abstract A48: Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice
Journal Articles

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Yong Jia, Jose Juarez, Jie Li, Mari Manuia, Matthew J. Niederst, Celin Tompkins, Noelito Timple, Mei-Ting Vaillancourt, AnneMarie Culazzo Pferdekamper, Elizabeth L. Lockerman, Chun Li, Jennifer Anderson, Carlotta Costa, Debbie Liao, Eric Murphy, Michael DiDonato, Badry Bursulaya, Gerald Lelais, Jordi Barretina, Matthew McNeill, Robert Epple, Thomas H. Marsilje, Nuzhat Pathan, Jeffrey A. Engelman, Pierre-Yves Michellys, Peter McNamara, Jennifer Harris, Steven Bender, Shailaja Kasibhatla
Journal: Cancer Research
Cancer Res (2016) 76 (6): 1591–1602.
https://doi.org/10.1158/0008-5472.CAN-15-2581
Published: 14 March 2016
View article titled, EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
Open the PDF for EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor in another window
Includes: Supplementary data
Journal Articles

Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations

Ryan B. Corcoran, Leanne G. Ahronian, Eliezer Van Allen, Erin M. Coffee, Nikhil Wagle, Eunice L. Kwak, Jason E. Faris, A. John Iafrate, Levi A. Garraway, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): NG04.
https://doi.org/10.1158/1538-7445.AM2015-NG04
Published: 01 August 2015
View article titled, Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations
Journal Articles

Abstract LB-055: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations

Leanne G. Ahronian, Erin M. Sennott, Eliezer M. Van Allen, Nikhil Wagle, Eunice L. Kwak, Jason E. Faris, Jason T. Godfrey, Koki Nishimura, Kerry D. Lynch, Craig H. Mermel, Elizabeth L. Lockerman, Anuj Kalsy, Joseph M. Gurski, Samira Bahl, Kristin Anderka, Lisa M. Green, Niall J. Lennon, Tiffany G. Huynh, Mari Mino-Kenudson, Gad Getz, Dora Dias-Santagata, A. John Iafrate, Jeffrey A. Engelman, Levi A. Garraway, Ryan B. Corcoran
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): LB-055.
https://doi.org/10.1158/1538-7445.AM2015-LB-055
Published: 01 August 2015
View article titled, Abstract LB-055: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations